Delivery time2024-01-04 11:48
Swiss pharmaceutical company Roche and Harvard University launch ‘Zosuravalpine’
Currently in first clinical trial… It will likely take several years to commercialize
Superbacteria (CG)
[연합뉴스TV 제공]
(Seoul = Yonhap News) Reporter Jinhyeong Park = CNN reported on the 3rd (local time) that a new antibiotic has been developed to treat so-called ‘superbugs’, antibiotic-resistant bacteria that do not die even when powerful antibiotics are used.
Roche, a global pharmaceutical company in Switzerland, and researchers at Harvard University in the United States have published research results showing that the antibiotic ‘Zosuravalpine’ they developed can effectively treat carbapenem-resistant Acinetobacter Baumannii (CRAB), which is resistant to the antibiotic carbapenem. I put it out.
Their research was published in the world-renowned scientific journal Nature.
According to the U.S. Centers for Disease Control and Prevention (CDC), CRAB causes serious infections of the lungs, urinary tract, and blood.
In 2017, it caused more than 8,500 hospital-acquired infections and 700 deaths in the United States, putting it at the top of the World Health Organization’s (WHO) list of important resistant bacteria.
CRAB is also known to be widely spread mainly in Asia and the Middle East, accounting for up to 20% of infection cases in intensive care units worldwide.
In addition, treatment is so difficult that there has been no case in which antibiotics to treat CRAB have been approved by the U.S. Food and Drug Administration (FDA) over the past 50 years.
According to a study published in the medical journal Lancet in 2022, resistant bacteria such as CRAB and methicillin-resistant Staphylococcus aureus (MRSA) caused approximately 1.3 million deaths worldwide in 2019, and are linked to the human immunodeficiency virus (HIV), which causes AIDS. It surpassed the approximately 860,000 deaths due to malaria and the 640,000 deaths due to malaria.
Additionally, in the United States, there are more than 2.8 million cases of resistant bacteria and more than 35,000 deaths each year, the CDC said in a 2019 report.
The researchers found that Josuravalpine was effective against more than 100 types of CRAB samples.
In addition, it was reported that administering josoravalpine to mice suffering from pneumonia due to CRAB infection significantly lowered the bacterial count and prevented death due to sepsis.
Josoravalpine is currently undergoing primary clinical trials to confirm its safety in the human body, so it is expected to take at least several more years until commercialization.
However, Professor César de la Fuente of the University of Pennsylvania, who did not participate in this study, told CNN that Josuravalpine is a very promising antibiotic.
However, the researchers said that the weakness of Josuravalpine is that it only kills specific bacteria, such as CRAB.
Regarding this, Professor de la Fuente pointed out that while many antibiotics kill even bacteria that are beneficial to humans, antibiotics that only act on specific bacteria may actually be better for overall health.
Report via KakaoTalk okjebo
<저작권자(c) 연합뉴스,
Unauthorized reproduction/redistribution, AI learning and use prohibited>
2024/01/04 11:48 Sent
2024-01-04 02:48:42
#antibiotic #developed #kill #antibioticresistant #superbugs
